title: Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma.
abstract: Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.
authors.affiliation: Departments of *Pediatrics †Orthopedic Surgery §Pathology, Graduate School of Medicine, Gifu University, Gifu ‡Department of Pediatrics, Okayama University Graduate School of Medicine, Okayama, Japan.
authors.forename: Michio
authors.initials: M
authors.lastname: Ozeki
authors.forename: Akifumi
authors.initials: A
authors.lastname: Nozawa
authors.forename: Kaori
authors.initials: K
authors.lastname: Kanda
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Hori
authors.forename: Akihito
authors.initials: A
authors.lastname: Nagano
authors.forename: Akira
authors.initials: A
authors.lastname: Shimada
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Fukao
mesh_terms: D000293:Adolescent; D000068338:Everolimus / Q000494:pharmacology / Q000627:therapeutic use*; D006390:Hemangioendothelioma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009362:Neoplasm Metastasis; D058570:TOR Serine-Threonine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases